Hiroko Wakimoto

12.3k total citations · 2 hit papers
76 papers, 3.8k citations indexed

About

Hiroko Wakimoto is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Epidemiology. According to data from OpenAlex, Hiroko Wakimoto has authored 76 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Molecular Biology, 44 papers in Cardiology and Cardiovascular Medicine and 10 papers in Epidemiology. Recurrent topics in Hiroko Wakimoto's work include Cardiomyopathy and Myosin Studies (26 papers), Cardiac electrophysiology and arrhythmias (19 papers) and Congenital heart defects research (17 papers). Hiroko Wakimoto is often cited by papers focused on Cardiomyopathy and Myosin Studies (26 papers), Cardiac electrophysiology and arrhythmias (19 papers) and Congenital heart defects research (17 papers). Hiroko Wakimoto collaborates with scholars based in United States, Japan and Israel. Hiroko Wakimoto's co-authors include Christine E. Seidman, Jonathan G. Seidman, Joshua Gorham, Charles I. Berul, Colin T. Maguire, Jianming Jiang, Josef Gehrmann, Peter E. Hammer, David A. Conner and Daniel M. DeLaughter and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Circulation.

In The Last Decade

Hiroko Wakimoto

74 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice

2016 467 citations Eric M. Green, Hiroko Wakimoto et al. Science profile →
Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice

2023 106 citations Daniel Reichart, Gregory A. Newby et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hiroko Wakimoto United States	32	2.5k	2.2k	439	351	236	76	3.8k
Joachim P. Schmitt Germany	21	2.3k 0.9×	2.1k 0.9×	417 0.9×	334 1.0×	268 1.1×	52	3.5k
Sakthivel Sadayappan United States	41	3.2k 1.3×	3.9k 1.7×	235 0.5×	562 1.6×	173 0.7×	179	5.5k
Andreas Perrot Germany	35	1.8k 0.7×	2.1k 1.0×	444 1.0×	162 0.5×	197 0.8×	71	3.1k
Christophe Depré United States	35	1.9k 0.8×	2.0k 0.9×	269 0.6×	631 1.8×	144 0.6×	71	4.2k
Arne Pfeufer Germany	26	1.7k 0.7×	1.5k 0.7×	185 0.4×	231 0.7×	412 1.7×	59	3.1k
Pascale Richard France	42	3.9k 1.6×	4.3k 1.9×	553 1.3×	284 0.8×	278 1.2×	168	6.6k
Lori A. Walker United States	34	1.7k 0.7×	1.1k 0.5×	218 0.5×	462 1.3×	134 0.6×	102	3.7k
Marijke Brink Switzerland	30	1.8k 0.7×	809 0.4×	244 0.6×	228 0.6×	267 1.1×	53	3.0k
Peter Razeghi United States	29	1.7k 0.7×	1.5k 0.7×	173 0.4×	504 1.4×	140 0.6×	44	3.4k
Andrew P. Landstrom United States	27	1.5k 0.6×	2.1k 1.0×	156 0.4×	125 0.4×	247 1.0×	96	3.0k

Countries citing papers authored by Hiroko Wakimoto

Since Specialization

Citations

This map shows the geographic impact of Hiroko Wakimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroko Wakimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroko Wakimoto more than expected).

Fields of papers citing papers by Hiroko Wakimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroko Wakimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroko Wakimoto. The network helps show where Hiroko Wakimoto may publish in the future.

Co-authorship network of co-authors of Hiroko Wakimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroko Wakimoto. A scholar is included among the top collaborators of Hiroko Wakimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroko Wakimoto. Hiroko Wakimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Lunde, Ida G., Debby M.E.I. Hellebrekers, Godelieve R.F. Claes, et al.. (2023). Prevalence and Clinical Consequences of Multiple Pathogenic Variants in Dilated Cardiomyopathy. Circulation Genomic and Precision Medicine. 16(2). e003788–e003788. 10 indexed citations

2.

Shimizu, K., Fatma Turna Demir, Mohammad A. Saad, et al.. (2023). Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies. Cancer Letters. 572. 216363–216363. 13 indexed citations

3.

Reichart, Daniel, Gregory A. Newby, Hiroko Wakimoto, et al.. (2023). Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nature Medicine. 29(2). 412–421. 106 indexed citations breakdown →

4.

Agarwal, Radhika, Hiroko Wakimoto, João A. Paulo, et al.. (2022). Pathogenesis of Cardiomyopathy Caused by Variants in ALPK3 , an Essential Pseudokinase in the Cardiomyocyte Nucleus and Sarcomere. Circulation. 146(22). 1674–1693. 17 indexed citations

5.

Hua, Lingyang, Alessandra Gurtner, Juri Kiyokawa, et al.. (2022). Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma. Biomedicine & Pharmacotherapy. 155. 113843–113843. 10 indexed citations

6.

Stanciu, Monica, Joshua Gorham, Hiroko Wakimoto, et al.. (2019). Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. Nature Communications. 10(1). 2910–2910. 83 indexed citations

7.

Wakimoto, Hiroko, Amanda C. Garfinkel, Barbara McDonough, et al.. (2018). MYBPC3 Mutations Cause Hypertrophic Cardiomyopathy by Dysregulating Myosin: Implications for Therapy. Circulation Research. 123. 1 indexed citations

8.

Green, Eric M., Hiroko Wakimoto, Robert L. Anderson, et al.. (2016). A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 351(6273). 617–621. 467 indexed citations breakdown →

9.

Burke, Michael A., Stephen Chang, Hiroko Wakimoto, et al.. (2016). Molecular profiling of dilated cardiomyopathy that progresses to heart failure. JCI Insight. 1(6). 73 indexed citations

10.

Huang, Zhan-Peng, Masaharu Kataoka, Jinghai Chen, et al.. (2015). Cardiomyocyte-enriched protein CIP protects against pathophysiological stresses and regulates cardiac homeostasis. Journal of Clinical Investigation. 125(11). 4122–4134. 29 indexed citations

11.

Hong, Eun‐Gyoung, Brian W. Kim, Dae Young Jung, et al.. (2013). Cardiac Expression of Human Type 2 Iodothyronine Deiodinase Increases Glucose Metabolism and Protects Against Doxorubicin-induced Cardiac Dysfunction in Male Mice. Endocrinology. 154(10). 3937–3946. 20 indexed citations

12.

Chang, Stephen, Danos C. Christodoulou, Joshua Gorham, et al.. (2011). IDENTIFYING NOVEL MOLECULAR MECHANISMS IN DILATED CARDIOMYOPATHY: INSIGHTS INTO TREATMENT AND PREVENTION. Journal of the American College of Cardiology. 57(14). E335–E335. 1 indexed citations

13.

Teekakirikul, Polakit, Seda Eminaga, Okan Toka, et al.. (2010). Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. Journal of Clinical Investigation. 120(10). 3520–3529. 353 indexed citations

14.

Wakimoto, Hiroko, Ronny Alcalai, Libin Wang, et al.. (2009). Abstract 2277: Verapamil Prevents Fatal Arrhythmia by Blocking Cardiac Ryanodine Receptor in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia Carrying Calsequestrin-2 Mutation. Circulation. 120. 1 indexed citations

15.

Wakimoto, Hiroko, et al.. (2008). Pulsed Field Gel Electrophoresis Analysis Conditions for Molecular Epidemiological Group B Streptococcus Identification. Kansenshogaku zasshi. 82(4). 351–353. 1 indexed citations

16.

Wolf, Cordula M., Libin Wang, Ronny Alcalai, et al.. (2007). Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. Journal of Molecular and Cellular Cardiology. 44(2). 293–303. 129 indexed citations

17.

Jay, Patrick Y., Colin T. Maguire, Hiroko Wakimoto, Seigo Izumo, & Charles I. Berul. (2005). Absence of Msx2 Does Not Affect Cardiac Conduction or Rescue Conduction Defects Associated with Nkx2‐5 Mutation. Journal of Cardiovascular Electrophysiology. 16(1). 81–85. 7 indexed citations

18.

Mitaka, Chieko, et al.. (2003). Relationships of Circulating Nitrite/Nitrate Levels to Severity and Multiple Organ Dysfunction Syndrome in Systemic Inflammatory Response Syndrome. Shock. 19(4). 305–309. 39 indexed citations

19.

Kasahara, Hideko, Hiroko Wakimoto, Margaret Liu, et al.. (2001). Progressive atrioventricular conduction defects and heart failure in mice expressing a mutant Csx/Nkx2.5 homeoprotein. Journal of Clinical Investigation. 108(2). 189–201. 14 indexed citations

20.

Kasahara, Hideko, Hiroko Wakimoto, Margaret Liu, et al.. (2001). Progressive atrioventricular conduction defects and heart failure in mice expressing a mutant Csx/Nkx2.5 homeoprotein. Journal of Clinical Investigation. 108(2). 189–201. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact